measurable residual disease

10 all articles · 20 / page

Ask MedXY AI

Latest news

Tag

All articles

Measurable Residual Disease as a Prognostic Biomarker in Frontline Azacitidine and Venetoclax-Treated AML: Insights from the French VENAURA Registry

In AML patients receiving frontline azacitidine and venetoclax, achieving measurable residual disease negativity strongly predicts longer survival and lower relapse rates, overriding baseline risk factors, as shown in the French VENAURA reg

Section: Hematology-OncologyJul 21, 2026

measurable residual disease

Latest news

Measurable Residual Disease as a Prognostic Biomarker in Frontline Azacitidine and Venetoclax-Treated AML: Insights from the French VENAURA Registry

Next-Generation Sequencing MRD Detection Predicts Outcomes in AML Patients Undergoing Allogeneic Stem Cell Transplantation

MRD Does Not Consistently Predict PFS Across Modern CLL Trials: Why Surrogacy Depends on Therapy, Duration, and Sample Source

Genomic Fusion Breakpoints: A Breakthrough in Pediatric ALL MRD Monitoring

MRD-Guided Intensification: A Tailored Approach to First-Line Chronic Lymphocytic Leukaemia Treatment

AlloHSCT in Adult Ph– ALL Treated with Pediatric-Inspired GIMEMA LAL1913: MRD Status at Transplant Drives Long-Term Outcomes

Tailoring Transplant Conditioning and Maintenance Therapy in FLT3-ITD AML: Insights on NPM1 Mutations and Measurable Residual Disease

Molecular Monitoring of MRD in Pediatric AML with KMT2A::MLLT10: Prognostic Insights and Clinical Impact

Advancing Chronic Lymphocytic Leukemia Management: The Impact of Measurable Residual Disease-Guided Ibrutinib-Venetoclax Therapy

MRD-Guided Consolidation Therapy in Newly Diagnosed Multiple Myeloma: Insights from the MIDAS Phase 3 Trial